Nav: Home

PharmaMar presents at ASCO the ADMYRE study's adjusted overall survival with plitidepsin

June 05, 2018

Abstract #8018

PharmaMar presents in oral session at ASCO the ADMYRE study's adjusted overall survival with plitidepsin
  • The modelled data on overall survival of the statistical evaluation of the impact of crossover on the ADMYRE study were presented.

  • Of the 84 patients treated in the comparator arm (dexamethasone as a single agent), 44% received the combination with plitidepsin after progression.

  • After analyzing the impact of crossover, the registered overall survival with plitidepsin was 11.6 months against the 6.4 months of dexamethasone alone.


Madrid, 5th June, 2018. - PharmaMar (MSE:PHM) has presented today how crossover has had an influence on the overall survival of the ADMYRE trial. The impact on overall survival of those patients that relapsed after receiving dexamethasone as a single agent and who were subsequently treated with plitidepsin in combination with dexamethasone was analyzed. Of the 84 patients treated from the comparator arm -dexamethasone as a single agent- 44%, 37 patients were treated with the combination with plitidepsin thereafter.

This data has been presented as a poster discussion session during the American Society of Clinical Oncology (ASCO) that is being held from the 1st to the 5th of June in Chicago (USA).

The ADMYRE study is a pivotal, randomized, open label, international, multicenter, phase III study, which included 255 multiple myeloma patients who had relapsed after having previously received at least 3, but no more than 6 prior lines and that compared both the safety and efficacy of plitidepsin plus dexamethasone against dexamethasone alone.

The primary endpoint of this study was Progression Free Survival -which resulted to be positive- was to demonstrate a statistically significant reduction in the risk of disease progression or death of 35% against the comparator.

During the presentation, the 2 statistical models used (RPSFT and the two stage method) to correct and measure the impact of crossover on overall survival were discussed, emphasizing the two stage model (Latimer et al.), that was considered the most adequate in the context of the Admyre study.

Accordingly, and taking into account the effect of crossover using the two stage method, a statistically significant increase in overall survival in the plitidepsin plus dexamethasone arm (11.6 months) against the comparator (6.4 months) was observed.

The studies presented at this meeting are available at http://abstracts.asco.org
-end-
About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers, Zepsyre® (PM1183), plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com.

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Pharmamar

Related Data Articles:

Discrimination, lack of diversity, & societal risks of data mining highlighted in big data
A special issue of Big Data presents a series of insightful articles that focus on Big Data and Social and Technical Trade-Offs.
Journal AAS publishes first data description paper: Data collection and sharing
AAS published its first data description paper on June 8, 2017.
73 percent of academics say access to research data helps them in their work; 34 percent do not publish their data
Combining results from bibliometric analyses, a global sample of researcher opinions and case-study interviews, a new report reveals that although the benefits of open research data are well known, in practice, confusion remains within the researcher community around when and how to share research data.
Designing new materials from 'small' data
A Northwestern and Los Alamos team developed a novel workflow combining machine learning and density functional theory calculations to create design guidelines for new materials that exhibit useful electronic properties, such as ferroelectricity and piezoelectricity.
Big data for the universe
Astronomers at Lomonosov Moscow State University in cooperation with their French colleagues and with the help of citizen scientists have released 'The Reference Catalog of galaxy SEDs,' which contains value-added information about 800,000 galaxies.
What to do with the data?
Rapid advances in computing constantly translate into new technologies in our everyday lives.
Why keep the raw data?
The increasingly popular subject of raw diffraction data deposition is examined in a Topical Review in IUCrJ.
Infrastructure data for everyone
How much electricity flows through the grid? When and where?
Finding patterns in corrupted data
A new 'robust' statistical method from MIT enables efficient model fitting with corrupted, high-dimensional data.
Big data for little creatures
A multi-disciplinary team of researchers at UC Riverside has received $3 million from the National Science Foundation Research Traineeship program to prepare the next generation of scientists and engineers who will learn how to exploit the power of big data to understand insects.

Related Data Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".